Los cúmulos de galaxias figuran entre las estructuras más masivas del universo que se mantienen unidas por la gravedad. Estas agrupaciones colosales, que abarcan desde cientos hasta miles de galaxias, se extienden a lo largo de millones de años-luz. Se mantienen unidas por grand …
After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug in neurology, endocrinology and rheumatology.
Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss Read More »
Landry joins in the aftermath of an investor’s call for the sale of the heart failure device company.
Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push Read More »
The CMS administrator’s comments Tuesday at an event hosted by an MA lobby suggest that the Trump administration remains interested in tougher oversight of the program, despite watering down or scrapping some of its biggest proposed reforms.
Oz: Medicare Advantage a garden ‘vulnerable to weeds and overgrowth’ Read More »
Medtech companies are preparing for a day when telesurgery, performed by a surgeon often hundreds of miles from the patient, could become a viable option for more people.
Telerobotic surgery is advancing around the world. Will the US embrace it? Read More »
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
Novartis bets up to $900M for radioligand therapy from China’s BoomRay Read More »
A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod Read More »
Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study Read More »
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS subtype in a Phase 3 trial. The partners plan to approach the FDA with the results to determine potential pathways for approval.
